With an estimated prevalence of around 1%, pulmonary hypertension (PH) presents a relevant burden worldwide. The revised European Society of Cardiology (ESC) /European Respiratory Society (ERS) guidelines for the diagnosis and treatment of PH [1] encompass current knowledge regarding epidemiology, pathophysiology, genetics, diagnostics and treatment. In this review, we aim to give an overview of some of the changes from the 2015 guidelines and their implication for the everyday clinical practice.
